Sildenafil attenuates pulmonary hypertension in acute porcine endotoxaemia

CURRENT STATUS: POSTED

Daniella A.G. Kemper
Universidade de Sao Paulo Faculdade de Medicina

Denise A. Otsuki
Universidade de Sao Paulo Faculdade de Medicina

Débora R.R. Maia
Universidade de Sao Paulo Faculdade de Medicina

Cristina O. Massoco
Universidade de Sao Paulo Faculdade de Medicina Veterinaria e Zootecnia

Rogério A. Marcasso
Faculdade de Medicina Veterinaria, Universidade Norte do Para

José Otávio Costa Auler Júnior
Universidade de Sao Paulo Faculdade de Medicina

Corresponding Author
auler.junior@hc.fm.usp.br
ORCID: https://orcid.org/0000-0002-3919-1743

Denise T. Fantoni
Universidade de Sao Paulo Faculdade de Medicina Veterinaria e Zootecnia

DOI: 10.21203/rs.2.11457/v1

SUBJECT AREAS
Anesthesiology & Pain Medicine

KEYWORDS
Phosphodiesterase V inhibitor; acute lung injury; LPS; septic shock; experimental model; swine.
Abstract

Background

Pulmonary hypertension is a risk factor for morbidity and mortality in septic shock. Pulmonary hypertension increases the right ventricular afterload, which tends to reduce the right ventricular output, leading to right ventricular dysfunction. Sildenafil has been largely used in the treatment of pulmonary arterial hypertension, but its effects in sepsis are unknown. The aim of this study was to investigate the hypothesis that sildenafil is able to attenuate endotoxin-induced pulmonary hypertension in a porcine model. Further, we investigated the effects on hemodynamic and oxygenation functions. We also evaluated lung morphology and the effect on plasma cytokine and troponin response. Methods Twenty pigs in which endotoxeamia was induced through intravenous bacterial lipopolysaccharide endotoxin (LPS) infusion (4µg/kg/h) were randomly assigned to Control group (n=10) – which received saline solution; or to Sildenafil group (n=10) – which received sildenafil orally (100 mg) previous the endotoxeamia. Results LPS induced a significant pulmonary hypertension with an increase in pulmonary arterial pressure, pulmonary vascular resistance index, end-diastolic volume of the right ventricle and also a decrease in PaO2/FiO2. Pulmonary and systemic arterial pressures were significantly lower in the Sildenafil group and sildenafil prevented the LPS effect on the end-diastolic volume of the right ventricle. Sildenafil maintained oxygenation with superior PaO2/FiO2 and lower oxygen extraction rate, but had no effect on intrapulmonary shunt. All cytokines and troponin increased after LPS infusion in both groups similarly. The LPS induced lung lesions, but there were no intergroup differences in the histological scoring system. Conclusion Sildenafil attenuated endotoxin-induced pulmonary hypertension preserving right heart function and maintained oxygenation without effecting shunt fractioning. However, caution should be taken due to the potential systemic vasodilatory effect. Sildenafil did not attenuate lung lesions and did not presented an anti-inflammatory effect in a porcine model of endotoxaemia.

Abstract

Background Pulmonary hypertension is a risk factor for morbidity and mortality in septic shock. Pulmonary hypertension increases the right ventricular afterload, which tends to reduce the right
ventricular output, leading to right ventricular dysfunction. Sildenafil has been largely used in the treatment of pulmonary arterial hypertension, but its effects in sepsis are unknown. The aim of this study was to investigate the hypothesis that sildenafil is able to attenuate endotoxin-induced pulmonary hypertension in a porcine model. Further, we investigated the effects on hemodynamic and oxygenation functions. We also evaluated lung morphology and the effect on plasma cytokine and troponin response. Methods Twenty pigs in which endotoxeamia was induced through intravenous bacterial lipopolysaccharide endotoxin (LPS) infusion (4µg/kg/h) were randomly assigned to Control group (n=10) – which received saline solution; or to Sildenafil group (n=10) – which received sildenafil orally (100 mg) previous the endotoxeamia. Results LPS induced a significant pulmonary hypertension with an increase in pulmonary arterial pressure, pulmonary vascular resistance index, end-diastolic volume of the right ventricle and also a decrease in PaO2/FiO2. Pulmonary and systemic arterial pressures were significantly lower in the Sildenafil group and sildenafil prevented the LPS effect on the end-diastolic volume of the right ventricle. Sildenafil maintained oxygenation with superior PaO2/FiO2 and lower oxygen extraction rate, but had no effect on intrapulmonary shunt. All cytokines and troponin increased after LPS infusion in both groups similarly. The LPS induced lung lesions, but there were no intergroup differences in the histological scoring system. Conclusion Sildenafil attenuated endotoxin-induced pulmonary hypertension preserving right heart function and maintained oxygenation without effecting shunt fractioning. However, caution should be taken due to the potential systemic vasodilatory effect. Sildenafil did not attenuate lung lesions and did not presented an anti-inflammatory effect in a porcine model of endotoxaemia.

Key words: Phosphodiesterase V inhibitor; acute lung injury; LPS; septic shock; experimental model; swine.

Background
Pulmonary hypertension is one of the major causes of morbidity and mortality in critically ill patients with septic shock [1]. The pathophysiology includes pulmonary hypertension, formation of extravascular lung water (EVLW), and deterioration of pulmonary gas exchange [2]. Among that,
pulmonary hypertension is considered an aggravator factor [3]. Pulmonary hypertension increases the right ventricular afterload, which tends to reduce the right ventricular output, leading to right ventricular dysfunction [4]. Its etiology is attributed to several factors such as pulmonary microthrombosis due to platelet activating factor release, or increase of inflammatory mediators such as tumor necrosis factor-α (TNF-a) and nitric oxide (NO) [3, 5-7] . There is no consensus on the therapeutic approach of pulmonary hypertension in sepsis. The effectiveness of a pulmonary vasodilator therapy has been limited by the lack of selectivity and potency. Most pulmonary vasodilators drugs have associated systemic vasodilator action, as well as an effect on pulmonary circulation not such prominent [4].

Sildenafil inhibits phosphodiesterase type V, increasing intracellular cGMP which causes hyperpolarization of smooth-muscle membranes and vascular relaxation [8]. Sildenafil has been largely used in the treatment of pulmonary arterial hypertension, with a significant reduction in pulmonary artery pressure values, improvement of functional capacity and quality of life [9]. Despite these attractive attributes, very little data are available for the use of sildenafil in sepsis. The aim of this study was to investigate the hypothesis that sildenafil is able to attenuate endotoxin-induced pulmonary hypertension in a porcine model. Further, we investigated the effects on hemodynamic, oxygenation parameters, and lung morphology. Lastly, we investigated the effect of sildenafil on the plasma cytokine levels and troponin release.

Methods

Animals

A total of 20 Large White pigs weighting 23.7±2.5kg were obtained from a commercial laboratory pig farm (Granja RG, Suzano, Brazil). The animals were fasted overnight with free access to water and transported to the laboratory facilities on the day of the experiment. The study was approved by Ethics Committee of the Faculdade de Medicina da Universidade de Sao Paulo (n.262/13).

Anaesthesia and preparation

Following premedication with ketamine (5mg/kg intramuscular) and midazolam (0.25mg/kg intramuscular), a catheter was inserted into the auricular vein and anaesthesia was induced with
propofol (5mg/kg intravenous). Anesthesia was maintained by isoflurane (1.4%). The lungs were mechanically ventilated (Primus ventilator, Dräger, Lübeck, Germany) with a tidal volume of 8ml/kg, 5cmH₂O of positive end-expiratory pressure (PEEP) and respiratory rate was adjusted to maintain EtCO₂ between 35-45mmHg, on volume controlled ventilation with a FiO₂ of 40%. Pancuronium (0.1mg/kg followed 5 µg/kg/min intravenous) and normal saline (5 ml/kg/h) were administered during the experiment. Core temperature was maintained between 37° and 39°C by using a heating pad. The right internal jugular vein was surgically exposed and a 7.5 F pulmonary artery catheter was inserted (Swan-Ganz Catheter, Baxter Healthcare Corporation; Irvine, CA, USA) into the pulmonary artery to measure cardiac output (thermodilution technique), mean pulmonary artery pressure (MPAP), and central venous pressure (CVP). Standard formulas were used to calculate the cardiac index (CI), the systemic and pulmonar vascular resistance index (SVRI and PVRI), and left and right ventricular stroke work indices (LVSWI and RVSWI). A catheter was inserted into the right femoral artery for continuous blood pressure monitoring (Pulsiocath Picco PV2015L20, Pulsion Medical Systems, München, Germany) and blood gas sampling. Oxygenation data (DO₂i, VO₂i, O₂ER and Qs/Qt) were calculated using standard equations. The right femoral vein was also cannulated for endotoxin infusion and fluid-administration.

Sildenafil dose
The dose of sildenafil was based on pilot studies in which increasing doses of sildenafil (20, 40, 80 and 100 mg) were administered till attenuation of pulmonary hypertension induced by LPS, which was defined as a MPAP value below 40 mmHg.

Experimental protocol
The animals were previously randomized into two groups: Control (CTL, n=10), and Sildenafil (SIL, n=10). After 30-min stabilization period, baseline parameters were collected and a single-dose of 100 mg sildenafil (Viagra, Pfizer) or saline was administered through a gastric tube. After 30-min of sildenafil/saline administration, endotoxaemia was induced by a bacterial lipopolysaccharide (LPS) endotoxin infusion at 4µg/kg/h intravenously (Escherichia coli O111:B4 LPS, 2.000.000 EU/mg,
product number L2630, Sigma-Aldrich, St. Louis, MO, USA).

Blood sampling, hemodynamic and oxygenation measurements were performed at baseline, prior to LPS infusion (T0), and every 30-min until 180 min of LPS infusion. A timeline for interventions and measurements is shown in Fig 1.

Animals were euthanized at the end of the experimental procedure by deepening anesthesia (5% isoflurane) and potassium chloride administration (19.1%, 10ml).

Fig 1.

Transesophageal echocardiography

The echocardiographic study was conducted by a qualified professional, using an ultrasound system with transesophageal transducer 7.5 / 5.0 MHz (En CHD Display, Minnesota, USA). Echocardiographic images of the heart were obtained in apical four-chamber views. We measured left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), right ventricular end-diastolic volume (RVEDV) and left ventricular ejection fraction (LVEF) was calculated by Simpson’s method.

Plasma cytokines and troponin

Seven ml of blood was withdrawn at baseline and at the end of the study (LPS180). The samples were centrifuged spun at 1200g and plasma was stored at -80°C for TNFα, IL-1β, IL6 and IL10 analysis, by standard kits of sandwich enzyme immunoassay technique (Quantikine, R&D Systems, Abingdon, UK). All measurements were performed in duplicate and according to the manufacturer’s instructions. The plasma troponin I was analyzed using chemiluminescence immunoassay technique employing the diagnostic set Immulite Turbo Troponin I in semi-automatic analyzer equipment (Immulate Analyzer - Diagnostic Products Corporation DPC).

Histology

Samples of the right diaphragmatic lung were collected for histological examination and stained with hematoxylin-eosin. The histological evaluation was performed by an experienced investigator blinded to group allocation. Ten random non-coincident fields (100x magnification) were evaluated using a scoring system (ranging from 0 to 4) for intra- and extra-alveolar hemorrhage, intra-alveolar edema, inflammatory infiltration of the interalveolar septa and airspace, atelectasis and overinflation [10].
Statistical analysis

Data are expressed as mean ± SD or median (interquartile range or minimum and maximum) for parametric and non-parametric data, respectively. Normality was tested using D’Agostino & Pearson test. For normally distributed data, a two-way ANOVA for repeated measures was applied with treatment (Sildenafil or Control) and time as fixed effects. P-values for the effects of both treatment and time are given, and a value ≤0.05 was considered significant. If a significant effect due to treatment was detected, the data were further analyzed post hoc using the Tukey´s test. For non-parametric data, Mann-Whitney test was used. All animals were included in the analysis. Statistical analysis were performed with Prism 6 for windows (GraphPad Software) and SigmaPlot 11 (Systat Sofware).

Results

Hemodynamic data

Heart rate and cardiac index increased significantly without differences between groups at LPS 60 and LPS90 (table 1). The MPAP and PVRI increased significantly in both groups; however the Sildenafil group showed significantly lower values compared to Control group during all the evaluation period except for PVRI at LPS90 (Fig 2). The MAP increased significantly at 30-min of LPS infusion (LPS30) in all animals, and then decreased significantly below baseline values in the Sildenafil group. The RVSWI increased significantly in all time points after LPS infusion in the control group, whereas in Sildenafil group the increase was significantly higher only at LPS30.

Table 1.

Fig 2.

Lactate and oxygenation data

There were significant increases in arterial lactate from 1.8 ± 0.6 (baseline) to 2.8 ± 0.8 mmol/l (LPS180) in the Control group and 2 ± 1.0 (baseline) to 3.25 ± 1.3 mmol/l (LPS180) in the Sildenafil group, with no difference between groups. The DO₂I increased significantly in all animals from LPS60 with no changes in VO₂I. The SvO₂ increased significantly in both groups, but was significantly higher at LPS30 in the Sildenafil group. The intrapulmonary shunt increased significantly over time in both
groups, with no difference between groups. The PaO₂/FiO₂ decreased significantly in the Control group at LPS30, LPS 120, LPS 150 and LPS180 and was significantly lower than the Sildenafil group at LPS30 and LPS180. The O₂-ER decreased in all animals from LPS60 to LPS150 with difference between groups at 30-min of LPS infusion, in which the Sildenafil group showed lower values (table 2).

Table 2.

Transesophageal echocardiography

There were no significant differences in the RVEDV in the Sildenafil group, but there were significant increases in the Control group with post hoc analyses identifying differences between groups at LPS30, LPS60, LPS120 and LPS180. LVEDV and LVESV decreased at LPS180 in both groups without differences between groups. For left ventricular ejection fraction, no differences were observed with time and between groups (table 3).

Table 3

Cytokines and troponin

Plasma TNFα, IL-1β, IL6 and IL10 increased significantly with time in both groups, with no differences between groups. Troponin concentration also increased in all animals, again without difference between groups (Fig 3).

Fig 3

Histology

Histological evaluation revealed a predominance of intense mononuclear infiltrates with thickening of the alveolar septum, overinflation, disrupted alveolar septum, congestion and areas of atelectasis in both groups. There were no differences in the histological scoring system between groups.

Table 4

Discussion

The major findings of this study are that in an experimental model of septic shock, (a) sildenafil attenuated endotoxin-induced pulmonary hypertension preserving right heart function, (b) sildenafil decreased systemic blood pressure, (c) sildenafil maintained oxygenation without effect in shunt fractioning, and (d) sildenafil did not influence lung morphology, plasma cytokines and troponin.
The endotoxaemia was successfully induced by LPS infusion, with significant increase in pulmonary arterial pressure, tachycardia, serum cytokines and cardiac troponin. A hyperdynamic state was observed after 30 minutes of LPS infusion, with a marked increase in pulmonary and systemic blood pressure. These LPS infusion effects were already described in other studies and are associated with massive release of thromboxane and endothelin-1 [11].

Although the LPS did not promote acute lung injury according to the Berlin definition, LPS induced histologic lung lesions similar to acute lung injury, with marked mononuclear infiltrates in lung tissues, over inflation, and atelectasis [12,13].

Sildenafil decreased pulmonary vascular resistance, pulmonary artery pressure, and RVSWI, decreasing afterload. Furthermore, animals that received sildenafil did not show changes in the end-diastolic volume of the right ventricle avoiding acute right heart dilation. The RV distention at end-diastole is a component of critical care echocardiography to diagnose RV failure as a potential cause of shock [14]. Sepsis-related myocardial dysfunction is not limited to only LV; the RV is also affected being present in about 30% of patients with severe sepsis [15,16]; by speckle tracking echocardiography, right ventricle dysfunction was detected in 72% of patients with severe sepsis or septic shock and was associated with high mortality [17].

Several mechanisms lead to sepsis-related cardiac RV dysfunction. Anatomical characteristics and hypoxia due to low perfusion make it difficult to compensate RV afterload increases as we observe in acute pulmonary injury increased pulmonary vascular resistance. [4,18]. Right ventricle dysfunction is associated with lower cardiac output, higher norepinephrine doses, higher troponin and lactate [16]. Therefore, Sildenafil may play a role in attenuating the severity of septic shock, avoiding RV dysfunction, but more studies are necessary.

The sildenafil effect in systemic arterial pressure has been previously reported and is dose-related [8,19,20]. In patients with primary pulmonary hypertension the decreased in MAP is clinically insignificant, but its effect in septic patients is probably deleterious [4,21] without a vasoactive support. In a porcine model of meconium-induced lung injury sildenafil reduced MAP even at the lowest dose used (0.4 mg/kg), demonstrating a markedly systemic vasodilator effect in acute lung...
injury probably due to inflammation [22]. The decrease in MAP observed in this study might be explained by the high dose used or the presence of a significant systemic inflammation. The DO\textsubscript{2}I increased after LPS infusion in both groups as consequence of increase in cardiac index, resulting in greater supply of oxygen to tissues. In contrast to the report by Keinsasser et al., where sildenafil caused increases in intrapulmonary shunt in anesthetized pigs which was reflected by marked decreases in PaO\textsubscript{2} [8], we found that sildenafil maintained oxygenation without effect in shunt fractioning. In patients with pulmonary hypertension associated to lung fibrosis, sildenafil has shown to cause selective pulmonary vasodilation on well ventilated areas and improve gas exchange. It was proposed that sildenafil could amplify pulmonary vasoregulatory mechanisms, enhancing pulmonary nitric oxide effects [23].

Sildenafil has demonstrated an anti-inflammatory effect in experimental models of acute lung injury and sepsis in rats [24]. We found no effect of sildenafil in cytokines. Although one reasonable explanation for these divergent findings may be the species differences, but we cannot exclude that sildenafil might have no anti-inflammatory effect in this LPS model.

Troponin has been shown to be an early indicator of pulmonary hypertension related RV dysfunction [25]. All animals had higher troponin concentration at the end of the study. Our findings support that troponin increases in lung injury [26,27]. Elevated plasma levels of troponin are associated with poor outcomes in pulmonary hypertension and in acute lung injury [25,27,28]. Sildenafil has been shown to decreases myocardial leak of troponin in rat model of myocardial hypertrophy [29], but this association in clinical settings of pulmonary hypertension is unknown. Although sildenafil was unable to reduce this cardiac marker in our study, further studies are necessary to evaluate this association. In contrast to the report by Kiss et al. [30], in which sildenafil presented a protective effect on lung morphology in monocrotaline (MCT)-induced rat pulmonary arterial hypertension model, we found no attenuation of endotoxin-induced lung lesions. One explanation for these divergent findings may be that sildenafil in acute lung injury have no anti-inflammatory effect, thus cannot attenuate lung lesions.
There are limitations in our study. Because of the lack of information on the pharmacokinetics and pharmacodynamics of sildenafil in porcine model, the measurement of serum levels of sildenafil would be valuable. Moreover, administration of sildenafil orally can cause differences in serum concentration and the injectable form would be more suitable for this purposed, but it is not available commercially. Finally, this was a model of acute porcine endotoxaemia induced by bacterial LPS, and hence cannot be extrapolated to longer-term outcomes nor to clinical practices as it may not accurately reflect human septic shock physiopathology.

However, considering the limitations of the study, it was possible to achieve the objective proposed to evaluate the effects of sildenafil in experimental endotoxemic shock in swine model, whose results may encourage future research with sildenafil in sepsis.

**Conclusion**

Sildenafil attenuated endotoxin-induced pulmonary hypertension, preserving right ventricle function and maintained oxygenation without effecting shunt fractioning. Finally, sildenafil did not present an anti-inflammatory effect in a porcine model of endotoxaemia. These data reinforce that sildenafil might be useful in patients with septic shock and cardiovascular and respiratory complications.

However, more data are needed to determine the risk:benefit ratio of this drug in clinical practice.

**Abbreviations**

CVP: central venous pressure; CTL: Control group; cGMP: guanosine cyclic monophosphate; EVLW: extravascular lung water; HR: heart rate; IC: cardiac index; LPS: lipopolysaccharide endotoxin; MPAP: mean pulmonary artery pressure; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; LVSWI: left ventricular stroke work index; NO: nitric oxide; PEEP: positive end-expiratory pressure; PVRI: pulmonary vascular resistance index; RVEDV: right ventricular end-diastolic volume; RVSWI: right ventricular stroke work index; SIL: Sildenafil group; SVRI: systemic vascular resistance index; TNF-a: tumor necrosis factor-a

**Declarations**

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Faculdade de Medicina da Universidade de Sao Paulo (n.262/13).
Consent for publication
Not applicable.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing of interest.

Funding
No funding.

Authors’ contributions
Conception and design: DTF, JOCA Jr, ; Data collection: DAGK, DAO, DRRM; Data analysis: DAO, COM, RAM; Drafting the manuscript: DAGK, DAO Revision of the manuscript after critical review: DTF, JOCA Jr. All authors read and approved the final manuscript.

Acknowledgments
We would like to thank the laboratory technician Gilberto de Mello Nascimento for all help and support on the experimental laboratory. We are grateful to Ligia Cristina Camara Cunha for her assistance during the review process.

Authors’ information
Daniella A.G. Kemper¹, Denise A. Otsuki¹, Débora R.R. Maia¹, Cristina O. Massoco², Rogério A. Marcasso³, José Otávio C. Auler Jr.¹, Denise T. Fantoni⁴

¹LIM08-Laboratory of Anesthesiology, HCFMUSP, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
²Departamento de Patologia, Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo, São Paulo, SP, Brazil
³Faculdade de Medicina Veterinária da Universidade Norte do Paraná, Arapongas, PR, Brazil
⁴Departamento de Cirurgia, Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo
References
1. Claessens YE, Dhainaut JF. Diagnosis and treatment of severe sepsis. Critical care. 2007;11 Suppl 5:S2.
2. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. The Journal of clinical investigation. 2012;122(8):2731-40.
3. Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH. Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest. 1978;73(5):583-91.
4. Chan CM, Klinger JR. The right ventricle in sepsis. Clinics in chest medicine. 2008;29(4):661-76, ix.
5. Court O, Kumar A, Parrillo JE, Kumar A. Clinical review: Myocardial depression in sepsis and septic shock. Critical care. 2002;6(6):500-8.
6. Ichinose F, Hataishi R, Wu JC, Kawai N, Rodrigues AC, Mallari C, et al. A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in endotoxemic mice. American journal of physiology Heart and circulatory physiology. 2003;285(6):H2524-30.
7. Clavijo LC, Carter MB, Matheson PJ, Wills-Frank LA, Wilson MA, Wead WB, et al. Platelet-activating factor and bacteremia-induced pulmonary hypertension. The Journal of surgical research. 2000;88(2):173-80.
8. Kleinsasser A, Loeckinger A, Hoermann C, Puehringer F, Mutz N, Bartsch G, et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. American journal of respiratory and critical care medicine. 2001;163(2):339-43.
9. Raja SG, Danton MD, MacArthur KJ, Pollock JC. Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. Journal of cardiothoracic and vascular anesthesia. 2006;20(5):722-35.
10. Krebs J, Kolz A, Tsagogiiorgas C, Pelosi P, Rocco PR, Luecke T. Effects of lipopolysaccharide-induced inflammation on initial lung fibrosis during open-lung mechanical ventilation in rats.
11. Wyns H, Plessers E, De Backer P, Meyer E, Croubels S. In vivo porcine lipopolysaccharide inflammation models to study immunomodulation of drugs. Veterinary immunology and immunopathology. 2015.

12. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 2007;369(9572):1553-64.

13. Wang HM, Bodenstein M, Markstaller K. Overview of the pathology of three widely used animal models of acute lung injury. European surgical research Europaische chirurgische Forschung Recherches chirurgicales europeennes. 2008;40(4):305-16.

14. Griffie MJ, Merkel MJ, Wei KS. The role of echocardiography in hemodynamic assessment of septic shock. Critical care clinics. 2010;26(2):365-82, table of contents.

15. Furian T, Aguiar C, Prado K, Ribeiro RV, Becker L, Martinelli N, et al. Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality. Journal of critical care. 2012;27(3):319 e9-15.

16. Pulido JN, Afessa B, Masaki M, Yuasa T, Gillespie S, Herasevich V, et al. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clinic proceedings. 2012;87(7):620-8.

17. Orde SR, Pulido JN, Masaki M, Gillespie S, Spoon JN, Kane GC, et al. Outcome prediction in sepsis: speckle tracking echocardiography based assessment of myocardial function. Critical care. 2014;18(4):R149.

18. Harmankaya A, Akilli H, Gul M, Akilli NB, Ergin M, Aribas A, et al. Assessment of right ventricular functions in patients with sepsis, severe sepsis and septic shock and its prognostic importance: a tissue Doppler study. Journal of critical care. 2013;28(6):1111 e7- e11.

19. Haase E, Bigam DL, Cravetchi O, Cheung PY. Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets. Shock. 2006;26(1):99-106.

20. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator
therapy. Mayo Clinic proceedings. 2003;78(10):1207-13.

21. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clinical cardiology. 2004;27(4 Suppl 1):I20-5.

22. Ryhammer PK, Shekerdemian LS, Penny DJ, Ravn HB. Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatric research. 2006;59(6):762-6.

23. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895-900.

24. Cadirci E, Halici Z, Odabasoglu F, Albayrak A, Karakus E, Unal D, et al. Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. Clinical and experimental immunology. 2011;166(3):374-84.

25. Roy AK, McCullagh BN, Segurado R, McGorrian C, Keane E, Keaney J, et al. Detection of high-sensitivity troponin in outpatients with stable pulmonary hypertension identifies a subgroup at higher risk of adverse outcomes. Journal of cardiac failure. 2014;20(1):31-7.

26. Naidech AM, Bassin SL, Garg RK, Ault ML, Bendok BR, Batjer HH, et al. Cardiac troponin I and acute lung injury after subarachnoid hemorrhage. Neurocritical care. 2009;11(2):177-82.

27. Bajwa EK, Boyce PD, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Critical care medicine. 2007;35(11):2484-90.

28. Heresi GA, Tang WH, Aytekin M, Hammel J, Hazen SL, Dweik RA. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. The European respiratory journal. 2012;39(4):939-44.

29. Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC pharmacology. 2005;5:10.

30. Kiss T, Kovacs K, Komocsi A, Tornyos A, Zalan P, Sumeugi B, et al. Novel mechanisms of sildenafil in
pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. PloS one. 2014;9(8):e104890.

Figure Legends
Fig 1. Time line for interventions and measurements.

LPS: lipopolysaccharide endotoxin

Fig 2. Mean arterial pressure, mean pulmonary arterial pressure, systemic vascular resistance index and pulmonary vascular resistance index in Control and Sildenafil group. † p<0.05 vs. baseline . *p<0.05 CTL vs. SIL.

MAP: mean arterial pressure; MPAP: mean pulmonary arterial pressure; SVRI: systemic vascular resistance index; PVRI: pulmonary vascular resistance index.

Fig 3. Cytokines and cardiac troponin in Control and Sildenafil group. * denotes significant intergroup differences (P<0.05). • denotes outliers

Tables
Due to technical limitations, tables 1 through 4 are only available as a download in the supplemental files section.

Figures

Figure 1

Fig 1. Time line for interventions and measurements. LPS: lipopolysaccharide endotoxin
Fig 2. Mean arterial pressure, mean pulmonary arterial pressure, systemic vascular resistance index and pulmonary vascular resistance index in Control and Sildenafil group. †

$p<0.05$ vs. baseline . *$p<0.05$ CTL vs. SIL. MAP: mean arterial pressure; MPAP: mean pulmonary arterial pressure; SVRI: systemic vascular resistance index; PVRI: pulmonary vascular resistance index.
Fig 3. Cytokines and cardiac troponin in Control and Sildenafil group. * denotes significant intergroup differences (P<0.05). • denotes outliers

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
